Resonance shared a post on LinkedIn:
“As we wrap up Q1 at Resonance, we are looking back at a selection of sessions that sparked meaningful discussions across our global networks. Catch up on these clinical insights:
Acute Leukemia Research and Care Network (ALRCaN Global)
- The AYA Debate: Does a pediatric or an adult protocol offer the best survival edge for AYA AML?
- Mastering Hematotox: Managing the CAR-T “hangover. Learn how the ALL-Hematotox score is refining predictive modeling for B-ALL.
Acute Leukemia Research and Care Network (ALRCaN LATAM)
- Post-Transplant Immunotherapy: We explore the critical role of immunotherapy after transplantation in patients with ALL.
- A Milestone in Uruguay: We analyze the experience and lessons learned from CAR-T therapy in Uruguay.
Global Neuroblastoma Network (GNN)
- Adaptive Risk Grouping: How can we tailor Neuroblastoma treatment in low- and middle- income countries? An essential look at the International Neuroblastoma Risk Group (INRG) project.
Across our networks, we are seeing a shift toward more personalized, risk-stratified care, from AYA AML to Neuroblastoma in LMICs. How is your institution adapting global data to fit your local patient needs?”
Other articles about Resonance on OncoDaily.
